From USFDA
Cadila Healthcare announced that Zydus Cadila has received tentative approval from US FDA to market Glipizide Extended Release tablets in the strengths of 2.5 mg, 5 mg and 10 mg. The drug falls in the ant-diabetic segment.The estimated sales in 2014 for Glipizide Extended Release tablets is USD 90.1 million, as per IMS.
Powered by Capital Market - Live News
